Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole – First Case Report and another Example of an Immunocompromised District
DOI:
https://doi.org/10.3889/oamjms.2018.026Keywords:
Erythema multiforme, Adverse skin reaction, Aromatase inhibitors, Anastrozole, Breast cancerAbstract
Anastrozole is a non-selective aromatase inhibitor for adjuvant breast cancer therapy in postmenopausal women. Cutaneous adverse events have been reported. We observed a 64-year-old female patient with a medical history of locally advanced breast cancer of her right breast that was treated with radiotherapy and adjuvant drug therapy with anastrozole. She developed a segmental bullous eruption limited to the cancer-affected breast. Cessation of the aromatase inhibitor and systemic therapy with prednisolone cleared the lesions completely. This is the first report of a segmental erythema multiforme like drug eruption by anastrozole and another example of the concept of the immunocompromised district of skin.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Sanford M, Plosker GL. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs. 2008; 68(9):1319-40. https://doi.org/10.2165/00003495-200868090-00007 PMid:18547136
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomised trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010; 16(6):1904-14. https://doi.org/10.1158/1078-0432.CCR-09-2282 PMid:20215537
Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori. 2015; 101(5):469-73. https://doi.org/10.5301/tj.5000376 PMid:26108239
Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart M, Cameron D; EORTC-Breast Cancer Group. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). Eur J Cancer. 2016; 53:144-54. https://doi.org/10.1016/j.ejca.2015.10.012 PMid:26724641
Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. Ann Rheum Dis. 2005; 64(4):651-2. https://doi.org/10.1136/ard.2004.023150 PMid:15769928 PMCid:PMC1755449
Jhaveri K, Halperin P, Shin SJ, Vahdat L. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast Cancer Res Treat. 2007; 106(3):315-8. https://doi.org/10.1007/s10549-007-9518-7 PMid:17972174
Wong M, Grossman J, Hahn BH, La Cava A. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol. 2008; 129(1):3-9. https://doi.org/10.1016/j.clim.2008.07.001 PMid:18640073 PMCid:PMC2579274
Bremec T, Demsar J, Luzar B, Pavlović MD. Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor. Dermatol Online J. 2009; 15(7):14. PMid:19903442
Santoro S, Santini M, Pepe C, Tognetti E, Cortelazzi C, Ficarelli E, De Panfilis G. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol. 2011; 25(5):596-8. https://doi.org/10.1111/j.1468-3083.2010.03803.x PMid:21492245
Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005; 23(2):171–81. https://doi.org/10.1016/j.clindermatol.2004.06.012 PMid:15802211
Su SC, Hung SI, Fan WL, Dao RL, Chung WH. Severe cutaneous adverse reactions: The pharmacogenomics from research to clinical implementation. Int J Mol Sci. 2016;1 7(11). pii: E1890.
Ruocco V, Ruocco E, Piccolo V, Brunetti G, Guerrera LP, Wolf R. The immunocompromised district in dermatology: A unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014; 32(5):569-76. https://doi.org/10.1016/j.clindermatol.2014.04.004 PMid:25160098
Nakatani K, Matsumoto M, Ue H, Nishioka A, Tanaka Y, Kodama H, Sasaguri S, Ogawa Y. Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer. Breast Cancer. 2008; 15(4):321-3. https://doi.org/10.1007/s12282-008-0041-4 PMid:18278432
Aiempanakit K, Amatawet C, Chiratikarnwong K, Auepemkiate S, Kayasut K, Suwiwat S, Apinantriyo B. Erythema multiforme-like cutaneous lesions in monomorphic epitheliotropic intestinal T-cell lymphoma: a rare case report. J Cutan Pathol. 2017; 44(2):183-88. https://doi.org/10.1111/cup.12864 PMid:27862162
Das A, Sarkar TK, Chandra S, Ghosh A, Gharami RC. A case series of erythema multiforme-like pityriasis rosea. Indian Dermatol Online J. 2016; 7(3):212-5. https://doi.org/10.4103/2229-5178.182374 PMid:27294066 PMCid:PMC4886603
Imbernón-Moya A, Aguilar A, Burgos F, Gallego MÃ. Erythema multiforme-like bullous pemphigoid. Actas Dermosifiliogr. 2016; 107(8):689-91. https://doi.org/10.1016/j.ad.2016.02.008 PMid:27048923
Wollina U, Hein G. Lupus erythematosus: uncommon presentations. Clin Dermatol. 2005; 23(5):470-9. https://doi.org/10.1016/j.clindermatol.2005.01.017 PMid:16179181
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0